CDC42 Suppression Blocks Leukemia Progression in Preclinical Tests Researchers have hunted for years to find ways to disrupt the uncanny survival and self-renewal abilities of acute myeloid leukemia (AML) cells. So far, experts have found very few specific signaling pathways that lead to a weakness that can be therapeutically exploited.
Read Featured Research| Research and Training Details | |
|---|---|
| Faculty | 26 |
| Joint Appointment Faculty | 2 |
| Research Fellows and Post Docs | 4 |
| Research Graduate Students | 3 |
| Total Annual Grant Award Dollars | $3,191,974 |
| Total Annual Industry Award Dollars | $2,281,245 |
| Clinical Activities and Training | |
|---|---|
| Staff Physicians | 6 |
| Clinical Fellows | 9 |
| Inpatient Encounters | 1,229 |
| Outpatient Encounters | 16,108 |